Annexin A1 expression is correlated with malignant potential of renal cell carcinoma

Yamanoi, Mariko; Yamanoi, Kazuhiro; Fujii, Chifumi; Nakayama, Jun

doi:10.1111/iju.13869

Cited by 13 publications

(15 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In breast cancer, ANXA1 overexpression is associated with resistance against 5-FU and trastuzumab treatments [38]. Additionally, ANXA1 expression was linked to reduced prognosis in gastric, bladder, breast, and renal cancers [14,[39][40][41].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Role of Annexin A1 in Squamous Cell Lung Cancer Progression

Elakad

Gieser

et al. 2021

Disease Markers

View full text Add to dashboard Cite

Lung cancer remains the primary cause of cancer-related death worldwide, and its molecular mechanisms of tumor progression need further characterization to improve the clinical management of affected patients. The role of Annexin A1 (ANXA1) in tumorigenesis and cancer progression in general and especially in lung cancer remains to be controversial and seems to be highly tissue specific and inconsistent among tumor initiation, progression, and metastasis. In the current study, we investigated ANXA1 expression in 81 squamous cell lung cancer (SQCLC), 86 pulmonary adenocarcinoma (AC), and 30 small cell lung cancer (SCLC) patient-derived tissue samples and its prognostic impact on patient’s survival. Mechanistically, we analyzed the impact of ANXA1 expression on proliferation and migration of SQCLC cell lines using CRISPR-Cas9 and mammalian overexpression vectors. Strong expression of ANXA1 was significantly correlated to longer overall survival only in SQCLC patients ( P = 0.019 ). Overexpression of ANXA1 promoted proliferation in SQCLC cell lines but suppressed their migration, while knockout of ANXA1 promoted cell migration and suppressed proliferation. In conclusion, ANXA1 expression might elongate patients’ survival by inhibiting tumor cell migration and subsequent metastasis.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The earliest discovered role of ANXA1 was its anti-inflammatory role to suppress neutrophils and modulated monocytes recruitment [9]. Dysregulation of ANXA1 expression has been reported to contribute to the pathophysiology of multiple processes, such as tumorigenesis and autoinflammatory diseases [10][11][12][13][14][15][16].…”

Section: Introductionmentioning

confidence: 99%

Role of Annexin A1 in Squamous Cell Lung Cancer Progression

Elakad

Gieser

et al. 2021

Disease Markers

View full text Add to dashboard Cite

show abstract

“…Model mice null for annexin A1 (Anxa1) show significantly suppressed tumor growth due to lack of angiogenesis, suggesting that Anxa1 is essential for tumor vascularization [10]. Anxa1 is reportedly present on the surface of tumor endothelial cells in several tumor types in mice and humans [11][12][13][14] and has been proposed to be a valid target for the tumor vasculature [15][16][17][18]. Previously, we discovered the carbohydrate mimetic peptide IFLLWQR (IF7) using peptide-displaying phage technology.…”

Section: Introductionmentioning

confidence: 99%

Tumor vasculature-targeted 10B delivery by an Annexin A1-binding peptide boosts effects of boron neutron capture therapy

Yoneyama

Hatakeyama

Yoneyama³

et al. 2021

BMC Cancer

View full text Add to dashboard Cite

Background p-Boronophenylalanine (10BPA) is a powerful 10B drug used in current clinical trials of BNCT. For BNCT to be successful, a high (500 mg/kg) dose of 10BPA must be administered over a few hours. Here, we report BNCT efficacy after rapid, ultralow-dose administration of either tumor vasculature-specific annexin A1-targeting IFLLWQR (IF7)-conjugated 10BPA or borocaptate sodium (10BSH). Methods (1) IF7 conjugates of either 10B drugs intravenously injected into MBT2 bladder tumor-bearing mice and biodistribution of 10B in tumors and normal organs analyzed by prompt gamma-ray analysis. (2) Therapeutic effect of IF7-10B drug-mediated BNCT was assessed by either MBT2 bladder tumor bearing C3H/He mice and YTS-1 tumor bearing nude mice. Results Intravenous injection of IF7C conjugates of either 10B drugs into MBT2 bladder tumor-bearing mice promoted rapid 10B accumulation in tumor and suppressed tumor growth. Moreover, multiple treatments at ultralow (10–20 mg/kg) doses of IF7-10B drug-mediated BNCT significantly suppressed tumor growth in a mouse model of human YTS-1 bladder cancer, with increased Anxa1 expression in tumors and infiltration by CD8-positive lymphocytes. Conclusions We conclude that IF7 serves as an efficient 10B delivery vehicle by targeting tumor tissues via the tumor vasculature and could serve as a relevant vehicle for BNCT drugs.

show abstract

“…In subgroup II, the model predicting MRD reveals bre ‐ as1 (also known as babam2 ‐ as1 ) and anxa1 as risk factor and ddit4 l and wwc3 as protective factor. Dysregulations of anxa1 have been detected in multiple tumours 31,32 . Gene wwc3 has been linked to Hippo signalling cascade related to tumorigenesis 33,34 .…”

Section: Resultsmentioning

confidence: 99%

Subgrouping by gene expression profiles to improve relapse risk prediction in paediatric B‐precursor acute lymphoblastic leukaemia

et al. 2021

View full text Add to dashboard Cite

Relapsed acute lymphoblastic leukaemia (ALL) remains a prevalent paediatric cancer and one of the most common causes of mortality from malignancy in children. Tailoring the intensity of therapy according to early stratification is a promising strategy but remains a major challenge due to heterogeneity and subtyping difficulty. In this study, we subgroup B‐precursor ALL patients by gene expression profiles, using non‐negative matrix factorization and minimum description length which unsupervisedly determines the number of subgroups. Within each of the four subgroups, logistic and Cox regression with elastic net regularization are used to build models predicting minimal residual disease (MRD) and relapse‐free survival (RFS) respectively. Measured by area under the receiver operating characteristic curve (AUC), subgrouping improves prediction of MRD in one subgroup which mostly overlaps with subtype TCF3‐PBX1 (AUC = 0·986 in the training set and 1·0 in the test set), compared to a global model published previously. The models predicting RFS displayed acceptable concordance in training set and discriminate high‐relapse‐risk patients in three subgroups of the test set (Wilcoxon test p = 0·048, 0·036, and 0·016). Genes playing roles in the models are specific to different subgroups. The improvement of subgrouped MRD prediction and the differences of genes in prediction models of subgroups suggest that the heterogeneity of B‐precursor ALL can be handled by subgrouping according to gene expression profiles to improve the prediction accuracy.

show abstract

Annexin A1 expression is correlated with malignant potential of renal cell carcinoma

Cited by 13 publications

References 24 publications

Role of Annexin A1 in Squamous Cell Lung Cancer Progression

Role of Annexin A1 in Squamous Cell Lung Cancer Progression

Tumor vasculature-targeted 10B delivery by an Annexin A1-binding peptide boosts effects of boron neutron capture therapy

Subgrouping by gene expression profiles to improve relapse risk prediction in paediatric B‐precursor acute lymphoblastic leukaemia

Contact Info

Product

Resources

About